The evolving pharmacotherapy of pulmonary fibrosis.

The evolving pharmacotherapy of pulmonary fibrosis.

Item
http://www.wikidata.org/entity/Q38069617
Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosisCellular mechanisms of tissue fibrosis. 6. Purinergic signaling and response in fibroblasts and tissue fibrosisStatin Use Is Associated with Reduced Mortality in Patients with Interstitial Lung Disease.Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain--results of a Delphi Panel.Hypoxia-sensitive pathways in inflammation-driven fibrosis.Epigenetic targets for novel therapies of lung diseases.Diagnosis and management of interstitial lung disease.Novel Drug Targets For Idiopathic Pulmonary Fibrosis.Efficacy of N-Acetylcysteine in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.Antioxidants and NOX1/NOX4 inhibition blocks TGFβ1-induced CCN2 and α-SMA expression in dermal and gingival fibroblasts.Anti-fibrotic nintedanib-a new opportunity for systemic sclerosis patients?The inhibition effect and mechanism of SY0916 on pulmonary fibrosis.
P2860

The evolving pharmacotherapy of pulmonary fibrosis.

Item
http://www.wikidata.org/entity/Q38069617
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The evolving pharmacotherapy of pulmonary fibrosis.
@en
type
label
The evolving pharmacotherapy of pulmonary fibrosis.
@en
prefLabel
The evolving pharmacotherapy of pulmonary fibrosis.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921
P356
P1433
P1476
The evolving pharmacotherapy of pulmonary fibrosis.
@en
P2093
P2860
P304
P31
P356
10.1517/14656566.2013.758250
P407
P433
P478
P577
P698
P921